Gabi Galperin
Research Subjects
Gabi Galperin has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alla Khashper
Department of Radiology, Shamir Medical Center, Beer Yaakov, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
1 shared publication - Asher Bashiri
Faculty of Health Sciences, Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel
1 shared publication - Atif Zeadna
IVF Unit, Division of Obstetrics and Gynecology, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 84101, Israel
1 shared publication - Benjamin Hayatt Taragin
Department of Radiology, Assuta Medical Center, Ben Gurion University of the Negev, Beer Sheva, Ashdod, Israel
1 shared publication - Orna Tal
Department of Medical Management, Shamir Medical Center, Bar Ilan University, Ramat Gan, Israel
1 shared publication - Tamar Wainstock
Department of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel
1 shared publication
Latest Publications
- Open Access
- 5 August 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 204, 113134
Discrepancies between preliminary and final radiology reports: Impact of training level, imaging modality, and clinical risk factors
- 5 August 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 204, 113134
Open AccessDiscrepancies between preliminary and final radiology reports: Impact of training level, imaging modality, and clinical risk factors
- Open Access
- 2 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1967
Increased Live Birth Rate with Dydrogesterone among Patients with Recurrent Pregnancy Loss Regardless of Other Treatments
Background: Recurrent pregnancy loss (RPL) is defined as the loss of two or more pregnancies. Several treatment options are available, including progesterone, which is one of the few treatments that improve live birth rates in RPL patients. Objective: To compare the live birth rates, medical and obstetric characteristics, and RPL evaluation results of women with and without progesterone treatment. These women attended the RPL clinic at Soroka University Medical Center. Methods: A retrospective cohort study based on 866 patients was conducted. The patients were divided into two groups and examined: the dydrogesterone treatment group consisting of 509 women and a group of 357 patients who did not receive the treatment. All the patients had a subsequent (index) pregnancy. Results: The two groups were not statistically different in terms of their demographic and clinical characteristics or evaluation results. In a univariate analysis, no statistically significant differences were found between the groups in terms of live birth rates (80.6% vs. 84%; p-value = 0.209). In a multivariate logistic analysis adjusted for maternal age, the ratio of pregnancy losses to the number of pregnancies, other administered treatments, antiphospholipid syndrome, and body mass index, dydrogesterone treatment was found to be independently associated with a higher rate of live births than the control group (adjusted OR = 1.592; CI 95% 1.051–2.413; p-value = 0.028). Conclusions: Progesterone treatment is associated with an increased live birth rate in RPL patients. Studies with larger sample sizes are recommended to strengthen these results.
- 2 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1967
Open AccessIncreased Live Birth Rate with Dydrogesterone among Patients with Recurrent Pregnancy Loss Regardless of Other Treatments
Background: Recurrent pregnancy loss (RPL) is defined as the loss of two or more pregnancies. Several treatment options are available, including progesterone, which is one of the few treatments that improve live birth rates in RPL patients. Objective: To compare the live birth rates, medical and obstetric characteristics, and RPL evaluation results of women with and without progesterone treatment. These women attended the RPL clinic at Soroka University Medical Center. Methods: A retrospective cohort study based on 866 patients was conducted. The patients were divided into two groups and examined: the dydrogesterone treatment group consisting of 509 women and a group of 357 patients who did not receive the treatment. All the patients had a subsequent (index) pregnancy. Results: The two groups were not statistically different in terms of their demographic and clinical characteristics or evaluation results. In a univariate analysis, no statistically significant differences were found between the groups in terms of live birth rates (80.6% vs. 84%; p-value = 0.209). In a multivariate logistic analysis adjusted for maternal age, the ratio of pregnancy losses to the number of pregnancies, other administered treatments, antiphospholipid syndrome, and body mass index, dydrogesterone treatment was found to be independently associated with a higher rate of live births than the control group (adjusted OR = 1.592; CI 95% 1.051–2.413; p-value = 0.028). Conclusions: Progesterone treatment is associated with an increased live birth rate in RPL patients. Studies with larger sample sizes are recommended to strengthen these results.